Nurix Therapeutics (NRIX) Operating Margin (2019 - 2025)
Nurix Therapeutics (NRIX) has disclosed Operating Margin for 7 consecutive years, with 612.03% as the latest value for Q4 2025.
- On a quarterly basis, Operating Margin fell 12530.0% to 612.03% in Q4 2025 year-over-year; TTM through Nov 2025 was 326.73%, a 6380.0% increase, with the full-year FY2025 number at 340.16%, up 5036.0% from a year prior.
- Operating Margin was 612.03% for Q4 2025 at Nurix Therapeutics, up from 805.37% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 87.25% in Q2 2023 to a low of 805.37% in Q3 2025.
- A 5-year average of 402.84% and a median of 400.65% in 2022 define the central range for Operating Margin.
- Peak YoY movement for Operating Margin: skyrocketed 41877bps in 2023, then crashed -37153bps in 2025.
- Nurix Therapeutics' Operating Margin stood at 513.16% in 2021, then tumbled by -40bps to 717.82% in 2022, then surged by 58bps to 299.06% in 2023, then plummeted by -63bps to 486.73% in 2024, then decreased by -26bps to 612.03% in 2025.
- Per Business Quant, the three most recent readings for NRIX's Operating Margin are 612.03% (Q4 2025), 805.37% (Q3 2025), and 109.68% (Q2 2025).